Trump Administration Plans to Reshore Production of 86 Key Drugs

According to a Sept. 25 Bloomberg report cited by Becker's Hospital Review, the Trump administration is developing an initiative to move manufacturing of 86 essential medicines to the U.S. within 18 months. Under the plan, the Office of Management and Budget would solicit proposals from healthcare industry stakeholders on how to reshore production of drugs on the list. The report does not specify an effective date or regulatory vehicle for the initiative. Because many of the listed medicines are generics commonly used in Medicaid populations, supply chain shifts could affect drug availability and pricing that state Medicaid pharmacy programs and MCOs manage.

Pharmacy